 BOSTON, June 02, 2022 GLOBE NEWSWIRE -- Albireo Pharma, Inc. Nasdaq: ALBO, a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer will be presenting at the following investor conferences: 